Developing a gene therapy to treat Duchenne muscular dystrophy (DMD).
Industry: Health Care
First Day Return: +41.4%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 12/29/2017 |
Offer Price | $16.00 |
Price Range $18.00 - $19.00 | |
Offer Shares (mm) | 7.8 |
Deal Size ($mm) | $125 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 01/25/2018 |
Offer Price | IPO Intelligence Only |
Price Range | IPO Intelligence Only |
Offer Shares (mm) | IPO Intelligence Only |
Deal Size ($mm) | $125 |
Lock-Up Date | IPO Intelligence Only |
Street Research | IPO Intelligence Only |
Underwriters |
---|
IPO Intelligence Only |
Company Data | |
---|---|
Headquarters | Cambridge, MA, United States |
Founded | 2013 |
Employees at IPO | 60 |
Website www.solidbio.com |